A. Rey

Comparison of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial

F. Shepherd, M. Nicolson, P. Woll, 2000 .

DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.

J. von Pawel, M. Reck, V. Gorbounova, 2014, Lung cancer.

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

G. Scagliotti, F. Shepherd, S. Novello, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

D. Dunlop, J. von Pawel, U. Gatzemeier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tirapazamine-cisplatin: the synergy.

U. Gatzemeier, V. Miller, J. Viallet, 1998, British Journal of Cancer.

DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

M. Reck, V. Gorbounova, F. Grossi, 2012 .

DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.

J. von Pawel, M. Reck, V. Gorbounova, 2014, Lung cancer.